1. 'Thinking that somebody's going to delay [a tonsillectomy] for one to two years is quite horrifying really': a qualitative feasibility study for the NAtional Trial of Tonsillectomy IN Adults (NATTINA Part 2). (10th November 2016) Authors: McSweeney, L.A.; O'Hara, J.T.; Rousseau, N.S.; Stocken, D.D.; Sullivan, F.; Vale, L.; Wilkes, S.; Wilson, J.A.; Haighton, C.A. Journal: Clinical otolaryngology Issue: Volume 42:Number 3(2017:Jun.) Page Start: 578 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations. (October 2022) Authors: Fischer, J.; Bouhana, K.; Chicarelli, M.J.; Dahlke, J.; Fell, B.; Fulton, J.; Guarnieri, A.; Haygood, L.; Jalluri, R.; Johnson, A.; McLean, B.; Max, M.; Rieger, R.; Robinson, J.; Rodriguez, M.; Sullivan, F.; Wang, Y.; Winski, S.; Zhou, Y. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Matching trial design decisions to the needs of those you hope will use the results: The PRECIS-2 tool. (December 2016) Authors: Loudon, K.; Zwarenstein, M.; Sullivan, F.; Donnan, P.; Treweek, S. Journal: International journal of surgery Issue: Volume 36(2016)Supplement 2 Page Start: S138 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Pre-clinical In Vitro and In Vivo Characterization of a Novel EGFR Sparing ErbB2 Inhibitor with Activity Against Oncogenic ErbB2 Mutations. (October 2022) Authors: Chicarelli, M.J.; Bouhana, K.; Cable, L.; Crow, M.; Fell, B.; Fischer, J.; Fulton, J.; Guarnieri, A.; Jalluri, R.; Robinson, J.; Sullivan, F.; Winski, S.; Zhou, Y. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Retrospective analysis of radium-223 treatment for adults with progressive castration-resistant metastatic prostate cancer with symptomatic bone metastasis. (February 2017) Authors: Gaffney, J.; O'Boyle, G.; Gaffney, B.; Roshan, D.; Sullivan, F.; Ibrahim, N.; Martin, J.; Small, C. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S194 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Should the Republic of Ireland introduce a national prostate-specific antigen testing programme for the secondary detection of prostate cancer? Results from a population-based cost-effectiveness analysis. (February 2017) Authors: Burns, R.; Drummond, F.; Sullivan, F.; O'Neill, C.; Sharp, L. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Technical assessment of whole body angiography and cardiac function within a single MRI examination. Issue 6 (June 2015) Authors: Gandy, S.J.; Lambert, M.; Belch, J.J.F.; Cavin, I.D.; Crowe, E.; Littleford, R.; Macfarlane, J.A.; Matthew, S.Z.; Martin, P.; Nicholas, R.S.; Struthers, A.D.; Sullivan, F.; Waugh, S.A.; White, R.D.; Weir-McCall, J.R.; Houston, J.G. Journal: Clinical radiology Issue: Volume 70:Issue 6(2015) Page Start: 595 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers. (December 2016) Authors: Brandhuber, B.; Haas, J.; Tuch, B.; Ebata, K.; Bouhana, K.; McFaddin, E.; Williams, L.; Winski, S.; Brown, E.; Burkhard, M.; Nanda, N.; Hamor, R.; Sullivan, F.; Hanson, L.; Morales, T.; Vigers, G.; Wallace, R.D.; Blake, J.; Andrews, S.; Rothenberg, S.M. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers. (December 2016) Authors: Blake, J.; Kolakowski, G.R.; Tuch, B.; Ebata, K.; Brandhuber, B.; Winski, S.; Bouhana, K.; Nanda, N.; Wu, W.I.; Parker, A.; Hamor, R.; Larsen, P.D.; Sullivan, F.; DeWolf, W.; Neitzel, N.; Wollenberg, L.; Andrews, S.; Rothenberg, S.M. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗